Imperial College London

Dr Samuel Turton

Faculty of MedicineDepartment of Medicine

Clinical Research Fellow







Burlington DanesHammersmith Campus





Dr. Samuel Turton is a MRC MARC clinical fellow completing a PhD in the Centre for Neuropsychopharmacology under the supervision of Prof Anne Lingford-Hughes and Prof David Nutt.

His research uses PET and MRI imaging to investigate the endogenous GABA and opioid neurotransmitter systems in alcohol addiction.

He is also involved in a number of other studies including the validation of a novel Imadazoline-2 binding site PET tracer BU99008.



Turton SP, Myers JFM, Mick IM, et al., Blunted Endogenous Opioid Release Following an Oral Dexamphetamine Challenge in Abstinent Alcohol Dependent Individuals, Molecular Psychiatry, ISSN:1359-4184

Tyacke RJ, Myers JFM, Venkataraman A, et al., 2018, Evaluation of 11C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain., J Nucl Med

Wall JSS, Iqbal J, Andrews M, et al., 2017, Development and validation of a clinical risk score to predict mortality after percutaneous coronary intervention., Open Heart, Vol:4, ISSN:2053-3624

Nahar LK, Cordero RE, Nutt D, et al., 2016, Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry, Journal of Analytical Toxicology, Vol:40, ISSN:0146-4760, Pages:117-123

Turton S, Lingford-Hughes A, 2016, Neurobiology and principles of addiction and tolerance, Medicine (united Kingdom), Vol:44, ISSN:1357-3039, Pages:693-696

More Publications